Gilead’s Replacement HIV Drug Improves Kidney Effects in Study
This article is for subscribers only.
Gilead Sciences Inc.’s next-generation HIV drug, called TAF, was safe for patients with mild to moderate kidney impairment, a study found, bettering the treatment’s chances of replacing a current standard therapy.
In a study of 242 HIV-positive patients, kidney function didn’t get worse and a marker of kidney disease decreased after they switched out older drugs for a TAF-based drug cocktail, the study found. Existing treatments have been found to harm the kidneys and bones.